Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions

Click to copy article linkArticle link copied!

This article is cited by 455 publications.

1. Philip Martin, Marco Giardiello, Tom O. McDonald, Steven P. Rannard, and Andrew Owen . Mediation of in Vitro Cytochrome P450 Activity by Common Pharmaceutical Excipients. Molecular Pharmaceutics 2013, 10 (7) , 2739-2748. https://doi.org/10.1021/mp400175n
2. Richard Lonsdale, Kerensa T. Houghton, Jolanta Żurek, Christine M. Bathelt, Nicolas Foloppe, Marcel J. de Groot, Jeremy N. Harvey, and Adrian J. Mulholland . Quantum Mechanics/Molecular Mechanics Modeling of Regioselectivity of Drug Metabolism in Cytochrome P450 2C9. Journal of the American Chemical Society 2013, 135 (21) , 8001-8015. https://doi.org/10.1021/ja402016p
3. Ya-Wen Hsiao, Carl Petersson, Mats A. Svensson, and Ulf Norinder . A Pragmatic Approach Using First-Principle Methods to Address Site of Metabolism with Implications for Reactive Metabolite Formation. Journal of Chemical Information and Modeling 2012, 52 (3) , 686-695. https://doi.org/10.1021/ci200523f
4. Drew R. Jones, So-Young Kim, Michael Guderyon, Chul-Ho Yun, Jeffery H. Moran and Grover P. Miller . Hydroxywarfarin Metabolites Potently Inhibit CYP2C9 Metabolism of S-Warfarin. Chemical Research in Toxicology 2010, 23 (5) , 939-945. https://doi.org/10.1021/tx1000283
5. Grover P. Miller, Drew R. Jones, Shane Z. Sullivan, Anna Mazur, Suzanne N. Owen, Neil C. Mitchell, Anna Radominska-Pandya and Jeffery H. Moran . Assessing Cytochrome P450 and UDP-Glucuronosyltransferase Contributions to Warfarin Metabolism in Humans. Chemical Research in Toxicology 2009, 22 (7) , 1239-1245. https://doi.org/10.1021/tx900031z
6. Poongavanam Vasanthanathan, Jozef Hritz, Olivier Taboureau, Lars Olsen, Flemming Steen Jørgensen, Nico P. E. Vermeulen and Chris Oostenbrink . Virtual Screening and Prediction of Site of Metabolism for Cytochrome P450 1A2 Ligands. Journal of Chemical Information and Modeling 2009, 49 (1) , 43-52. https://doi.org/10.1021/ci800371f
7. Christine M. Bathelt, Adrian J. Mulholland and Jeremy N. Harvey. QM/MM Modeling of Benzene Hydroxylation in Human Cytochrome P450 2C9. The Journal of Physical Chemistry A 2008, 112 (50) , 13149-13156. https://doi.org/10.1021/jp8016908
8. Patrik Rydberg, Ulf Ryde and Lars Olsen. Prediction of Activation Energies for Aromatic Oxidation by Cytochrome P450. The Journal of Physical Chemistry A 2008, 112 (50) , 13058-13065. https://doi.org/10.1021/jp803854v
9. Carrie M. Mosher, Matthew A. Hummel, Timothy S. Tracy and Allan E. Rettie . Functional Analysis of Phenylalanine Residues in the Active Site of Cytochrome P450 2C9. Biochemistry 2008, 47 (45) , 11725-11734. https://doi.org/10.1021/bi801231m
10. M. Paul Gleeson. Generation of a Set of Simple, Interpretable ADMET Rules of Thumb. Journal of Medicinal Chemistry 2008, 51 (4) , 817-834. https://doi.org/10.1021/jm701122q
11. Mohammed S. Al-Dosari,, Joseph E. Knapp, and, Dexi Liu. Activation of Human CYP2C9 Promoter and Regulation by CAR and PXR in Mouse Liver. Molecular Pharmaceutics 2006, 3 (3) , 322-328. https://doi.org/10.1021/mp0500824
12. Charles W. Locuson, II,, Hisashi Suzuki,, Allan E. Rettie, and, Jeffrey P. Jones. Charge and Substituent Effects on Affinity and Metabolism of Benzbromarone-Based CYP2C19 Inhibitors. Journal of Medicinal Chemistry 2004, 47 (27) , 6768-6776. https://doi.org/10.1021/jm049605m
13. Charles W. Locuson, II,, Denise A. Rock, and, Jeffrey P. Jones. Quantitative Binding Models for CYP2C9 Based on Benzbromarone Analogues. Biochemistry 2004, 43 (22) , 6948-6958. https://doi.org/10.1021/bi049651o
14. Ismael Zamora,, Lovisa Afzelius, and, Gabriele Cruciani. Predicting Drug Metabolism:  A Site of Metabolism Prediction Tool Applied to the Cytochrome P450 2C9. Journal of Medicinal Chemistry 2003, 46 (12) , 2313-2324. https://doi.org/10.1021/jm021104i
15. Robert L. Haining,, Jeffrey P. Jones,, Kirk R. Henne,, Michael B. Fisher,, Dennis R. Koop,, William F. Trager, and, Allan E. Rettie. Enzymatic Determinants of the Substrate Specificity of CYP2C9:  Role of B‘−C Loop Residues in Providing the π-Stacking Anchor Site for Warfarin Binding. Biochemistry 1999, 38 (11) , 3285-3292. https://doi.org/10.1021/bi982161+
16. Frank Jung,, Keith J. Griffin,, Wu Song,, Toby H. Richardson,, Mierha Yang, and, Eric F. Johnson. Identification of Amino Acid Substitutions that Confer a High Affinity for Sulfaphenazole Binding and a High Catalytic Efficiency for Warfarin Metabolism To P450 2C19. Biochemistry 1998, 37 (46) , 16270-16279. https://doi.org/10.1021/bi981704c
17. Dieter H. Lang,, Allan E. Rettie, and, Ronald H. Böcker. Identification of Enzymes Involved in the Metabolism of Atrazine, Terbuthylazine, Ametryne, and Terbutryne in Human Liver Microsomes. Chemical Research in Toxicology 1997, 10 (9) , 1037-1044. https://doi.org/10.1021/tx970081l
18. Nikhilesh Andhi, Bhuvana Darawadi. The Genetic Blueprint of Cardiovascular Therapy: Pharmacogenomics for Improved Efficacy and Safety. Journal of Indian College of Cardiology 2024, 14 (3) , 79-87. https://doi.org/10.4103/jicc.jicc_14_24
19. Zhendong Chen, Max Taubert, Chunli Chen, Jana Boland, Qian Dong, Muhammad Bilal, Charalambos Dokos, Bertil Wachall, Manfred Wargenau, Bernhard Scheidel, Martin H. J. Wiesen, Elke Schaeffeler, Roman Tremmel, Matthias Schwab, Uwe Fuhr. A Semi-Mechanistic Population Pharmacokinetic Model of Noscapine in Healthy Subjects Considering Hepatic First-Pass Extraction and CYP2C9 Genotypes. Drugs in R&D 2024, 24 (2) , 187-199. https://doi.org/10.1007/s40268-024-00466-6
20. W.J. von Törne, L. Steinhäuser, U.-A. Klyk-Seitz, C. Piechotta. High-resolution mass spectrometric elucidation of electron ionization induced fragmentation pathways of methylated warfarin and selected hydroxylated species. International Journal of Mass Spectrometry 2024, 499 , 117220. https://doi.org/10.1016/j.ijms.2024.117220
21. David Renaud, Alexander Höller, Miriam Michel. Potential Drug–Nutrient Interactions of 45 Vitamins, Minerals, Trace Elements, and Associated Dietary Compounds with Acetylsalicylic Acid and Warfarin—A Review of the Literature. Nutrients 2024, 16 (7) , 950. https://doi.org/10.3390/nu16070950
22. Wipert Jannik von Törne, Urszula-Anna Klyk-Seitz, Christian Piechotta. Developing a GC-EI-MS/MS method for quantifying warfarin and five hydroxylated metabolites generated by the Fenton reaction. Environmental Science and Pollution Research 2024, 31 (11) , 16986-16994. https://doi.org/10.1007/s11356-024-32133-3
23. Isabelle Zenklusen, Jasper Dingemanse, Christian Reh, Martine Gehin, Priska Kaufmann. Effect of Daridorexant on the Pharmacokinetics of Midazolam, and on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Male Subjects. Drugs in R&D 2024, 24 (1) , 97-108. https://doi.org/10.1007/s40268-024-00456-8
24. So Yeon Jeon, Jin-Hyang Park, Mi Jeong Kwon, Min-Koo Choi, Im-Sook Song. Effects of red ginseng extract on the pharmacokinetics and disposition of warfarin via intestinal Cyp2c11 modulation in rats. Journal of Pharmaceutical Investigation 2024, 54 (1) , 85-97. https://doi.org/10.1007/s40005-023-00650-x
25. Patrick J. Silva, Kenneth S. Ramos. Trends and implementation of preemptive pharmacogenomic testing. 2024, 363-381. https://doi.org/10.1016/B978-0-12-824010-6.00053-8
26. Lauren E. Walker, Anna Stewart, Sir Munir Pirmohamed, James F. Meschia, Frances Bartlett Kinne. Stroke Pharmacogenetics. 2024, 423-508. https://doi.org/10.1007/978-3-031-41777-1_17
27. Ejaz Ahmad, Muhammad Jahangir, Muhammad Akhter Ismail, Hafsa Afzal, Shehar Bano, Rahat Shamim, Nadeem Irfan Bukhari. Influence of Quercetin Pretreatment on Pharmacokinetics of Warfarin in Rats. Current Drug Safety 2023, 18 (4) , 547-554. https://doi.org/10.2174/1574886317666221014101201
28. Erkka Järvinen, Ann‐Cathrine Dalgård Dunvald, Martin Thomsen Ernst, Helen S. Hammer, Oliver Pötz, Anton Pottegård, Tore B. Stage. Dicloxacillin‐warfarin drug–drug interaction—A register‐based study and in vitro investigations in 3D spheroid primary human hepatocytes. British Journal of Clinical Pharmacology 2023, 89 (8) , 2614-2624. https://doi.org/10.1111/bcp.15738
29. Islam Eljilany, Hazem Elewa, Daoud Al-Badriyeh. Cost-Benefit Analysis of Genotype-Guided Interruption Days in Warfarin Pre-Procedural Management. Current Problems in Cardiology 2023, 48 (6) , 101128. https://doi.org/10.1016/j.cpcardiol.2022.101128
30. Robert S. Foti, Joseph M. Roesner, Joshua T. Pearson. Application of reaction phenotyping to address pharmacokinetic variability in patient populations. 2023, 249-267. https://doi.org/10.1016/B978-0-12-817134-9.00019-2
31. Adrijana Kekic. Pharmacogenomics in Cardiovascular Diseases. 2023, 201-237. https://doi.org/10.1007/978-3-031-45903-0_11
32. DAN A. ROCK, LARRY C. WIENKERS. Characterization of Cytochrome P450 Mechanism Based Inhibition. 2022, 465-526. https://doi.org/10.1002/9781119851042.ch15
33. Shen Cheng, Darcy R. Flora, Allan E. Rettie, Richard C. Brundage, Timothy S. Tracy. Pharmacokinetic Modeling of Warfarin І – Model-Based Analysis of Warfarin Enantiomers with a Target Mediated Drug Disposition Model Reveals CYP2C9 Genotype-Dependent Drug-Drug Interactions of S-Warfarin. Drug Metabolism and Disposition 2022, 50 (9) , 1287-1301. https://doi.org/10.1124/dmd.122.000876
34. Shen Cheng, Darcy R. Flora, Allan E. Rettie, Richard C. Brundage, Timothy S. Tracy. Pharmacokinetic Modeling of Warfarin ІI – Model-Based Analysis of Warfarin Metabolites after Warfarin Administered Either Alone or Together with Fluconazole or Rifampin. Drug Metabolism and Disposition 2022, 50 (9) , 1302-1311. https://doi.org/10.1124/dmd.122.000877
35. Yasushi Yamazoe, Yoshiya Yamamura, Kouichi Yoshinari. Construction of a fused grid-based template system of CYP2C9 and its application. Drug Metabolism and Pharmacokinetics 2022, 45 , 100451. https://doi.org/10.1016/j.dmpk.2022.100451
36. Daniel Felipe Silgado-Guzmán, Mariana Angulo-Aguado, Adrien Morel, María José Niño-Orrego, Daniel-Armando Ruiz-Torres, Nora Constanza Contreras Bravo, Carlos Martin Restrepo, Oscar Ortega-Recalde, Dora Janeth Fonseca-Mendoza. Characterization of ADME Gene Variation in Colombian Population by Exome Sequencing. Frontiers in Pharmacology 2022, 13 https://doi.org/10.3389/fphar.2022.931531
37. Hao Sun, Kristen A. Cardinal, Larry Wienkers, Alice Chin, Vineet Kumar, Calvin Neace, Clark Henderson, Christopher J. Endres, Ariel Topletz-Erickson, Kelly Regal, Alex Vo, Stephen C. Alley, Anthony J. Lee. Elimination of tucatinib, a small molecule kinase inhibitor of HER2, is primarily governed by CYP2C8 enantioselective oxidation of gem-dimethyl. Cancer Chemotherapy and Pharmacology 2022, 89 (6) , 737-750. https://doi.org/10.1007/s00280-022-04429-z
38. Shasha Jin, Zhihong Li, Qing Yang, Boyu Fang, Xiaoqiang Xiang, Chao Peng, Weimin Cai. Simultaneous Characterization and Determination of Warfarin and Its Hydroxylation Metabolites in Rat Plasma by Chiral Liquid Chromatography-Tandem Mass Spectrometry. Pharmaceutics 2022, 14 (6) , 1141. https://doi.org/10.3390/pharmaceutics14061141
39. Chang‑Keun Cho, Pureum Kang, Hye-Jung Park, Eunvin Ko, Chou Yen Mu, Yun Jeong Lee, Chang-Ik Choi, Hyung Sik Kim, Choon-Gon Jang, Jung‑Woo Bae, Seok-Yong Lee. Physiologically based pharmacokinetic (PBPK) modeling of piroxicam with regard to CYP2C9 genetic polymorphism. Archives of Pharmacal Research 2022, 45 (5) , 352-366. https://doi.org/10.1007/s12272-022-01388-0
40. Dakota L. Pouncey, Dustyn A. Barnette, Riley W. Sinnott, Sarah J. Phillips, Noah R. Flynn, Howard P. Hendrickson, S. Joshua Swamidass, Grover P. Miller. Discovery of Novel Reductive Elimination Pathway for 10-Hydroxywarfarin. Frontiers in Pharmacology 2022, 12 https://doi.org/10.3389/fphar.2021.805133
41. Wipert von Törne, Lorin Steinhäuser, Urszula-Anna Klyk-Seitz, Christian Piechotta. High-Resolution Mass Spectrometric Elucidation of Electron Impact Induced Fragmentation Pathways of Methylated Warfarin and Selected Hydroxylated Species. SSRN Electronic Journal 2022, 23 https://doi.org/10.2139/ssrn.4046356
42. Ann K. Daly. Pharmacogenetics of the cytochromes P450: Selected pharmacological and toxicological aspects. 2022, 49-72. https://doi.org/10.1016/bs.apha.2022.05.001
43. AliMohammed Abd Alridha, KarrarMohammed Al-Gburi, SarahKadhim Abbood. Warfarin therapy and pharmacogenetics: A narrative review of regional and Iraqi studies. Medical Journal of Babylon 2022, 19 (3) , 324. https://doi.org/10.4103/MJBL.MJBL_70_22
44. Heemoon Lee, Hyun Joo Kim, Hyoung Woo Chang, Dong Jung Kim, Jonghoon Mo, Ji-Eon Kim. Development of a system to support warfarin dose decisions using deep neural networks. Scientific Reports 2021, 11 (1) https://doi.org/10.1038/s41598-021-94305-2
45. Arinao Ndadza, Sarudzai Muyambo, Pindile Mntla, Ambroise Wonkam, Emile Chimusa, Andre P. Kengne, Mpiko Ntsekhe, Collet Dandara. Profiling of warfarin pharmacokinetics‐associated genetic variants: Black Africans portray unique genetic markers important for an African specific warfarin pharmacogenetics‐dosing algorithm. Journal of Thrombosis and Haemostasis 2021, 19 (12) , 2957-2973. https://doi.org/10.1111/jth.15494
46. Sonia J. Parikh, Sumit Kamat, Margaret Phillips, Samuel P. Boyson, Thomas Yarbrough, Dylan Davie, Qinghai Zhang, Karen C. Glass, Manish B. Shah. Insights into the Genetic Variations of Human Cytochrome P450 2C9: Structural Analysis, Characterization and Comparison. International Journal of Molecular Sciences 2021, 22 (19) , 10206. https://doi.org/10.3390/ijms221910206
47. Katrin Sangkuhl, Karla Claudio‐Campos, Larisa H. Cavallari, Jose A.G. Agundez, Michelle Whirl‐Carrillo, Jorge Duconge, Andria L. Del Tredici, Mia Wadelius, Mariana Rodrigues Botton, Erica L. Woodahl, Stuart A. Scott, Teri E. Klein, Victoria M. Pratt, Ann K. Daly, Andrea Gaedigk. PharmVar GeneFocus: CYP2C9. Clinical Pharmacology & Therapeutics 2021, 110 (3) , 662-676. https://doi.org/10.1002/cpt.2333
48. Lana Tran, Mina Nikanjam, Edmund V. Capparelli, Joseph S. Bertino, Anne N. Nafziger, Angela D.M. Kashuba, Sandrine Turpault, Joseph D. Ma. S-warfarin limited sampling strategy with a population pharmacokinetic approach to estimate exposure and cytochrome P450 (CYP) 2C9 activity in healthy adults. European Journal of Clinical Pharmacology 2021, 77 (9) , 1349-1356. https://doi.org/10.1007/s00228-021-03123-y
49. Ayaka Shiozawa, Satoshi Yamaori, Shinobu Kamijo, Shigeru Ohmori. Effects of acid and lactone forms of statins on S-warfarin 7-hydroxylation catalyzed by human liver microsomes and recombinant CYP2C9 variants (CYP2C9.1 and CYP2C9.3). Drug Metabolism and Pharmacokinetics 2021, 36 , 100364. https://doi.org/10.1016/j.dmpk.2020.10.003
50. D. Fernando Estrada, Amit Kumar, Christopher S. Campomizzi, Natalie Jay. Crystal Structures of Drug-Metabolizing CYPs. 2021, 171-192. https://doi.org/10.1007/978-1-0716-1554-6_7
51. Claudia Chieffi, Cristian Camuto, Fabio De-Giorgio, Xavier de la Torre, Francesca Diamanti, Monica Mazzarino, Claudio Trapella, Matteo Marti, Francesco Botrè. Metabolic profile of the synthetic drug 4,4′-dimethylaminorex in urine by LC–MS-based techniques: selection of the most suitable markers of its intake. Forensic Toxicology 2021, 39 (1) , 89-100. https://doi.org/10.1007/s11419-020-00544-9
52. Islam Eljilany, Mohamed Elarref, Nabil Shallik, Abdel-Naser Elzouki, Loulia Bader, Ahmed El-Bardissy, Osama Abdelsamad, Daoud Al-Badriyeh, Larisa H Cavallari, Hazem Elewa. Genetic and Non-Genetic Factors Impact on INR Normalization in Preprocedural Warfarin Management. Pharmacogenomics and Personalized Medicine 2021, Volume 14 , 1069-1080. https://doi.org/10.2147/PGPM.S322743
53. Tse-Yin Huang, Chung-Ping Yu, Yow-Wen Hsieh, Shiuan-Pey Lin, Yu-Chi Hou. Resveratrol stereoselectively affected (±)warfarin pharmacokinetics and enhanced the anticoagulation effect. Scientific Reports 2020, 10 (1) https://doi.org/10.1038/s41598-020-72694-0
54. Sonia J. Parikh, Chiara M. Evans, Juliet O. Obi, Qinghai Zhang, Keiko Maekawa, Karen C. Glass, Manish B. Shah. Structure of Cytochrome P450 2C9*2 in Complex with Losartan: Insights into the Effect of Genetic Polymorphism. Molecular Pharmacology 2020, 98 (5) , 529-539. https://doi.org/10.1124/molpharm.120.000042
55. N. A. Chernikova, L. L. Kamynina, A. S. Ametov, D. A. Sychev, E. A. Grishina, K. A. Ryzhikova. The pharmacogenetics of hypoglycemia and the glycemic variability at the patients ith type 2 diabetes mellitus. Terapevticheskii arkhiv 2020, 92 (10) , 54-62. https://doi.org/10.26442/00403660.2020.10.000530
56. Feng Zhang, Jian Huang, Rong-Jing He, Lu Wang, Peng-Chao Huo, Xiao-Qing Guan, Sheng-Quan Fang, Yan-Wei Xiang, Shou-Ning Jia, Guang-Bo Ge. Herb-drug interaction between Styrax and warfarin: Molecular basis and mechanism. Phytomedicine 2020, 77 , 153287. https://doi.org/10.1016/j.phymed.2020.153287
57. Tutku ERARSLAN, İbrahim TÜRKÇÜER, Aylin KÖSELER, Ramazan SABİRLİ, Atakan YILMAZ, Mert ÖZEN, Abuzer KEKEÇ, Fatih ÇİFÇİBAŞI. Antikoagülan tedavisi alan hastalarda CYP2C9 gen polimorfizminin araştırılması. Pamukkale Medical Journal 2020, https://doi.org/10.31362/patd.743452
58. Yuki Kitamura, Ken-ichi Saeki. Phenotypic analysis of human CYP2C9 polymorphisms using fluorine-substituted tolbutamide. Drug Discoveries & Therapeutics 2020, 14 (4) , 204-208. https://doi.org/10.5582/ddt.2020.03060
59. Kazuhiko Asari, Harumi Takahashi. Prediction of the Impact of CYP2C9 and VKORC1 Genotypes on Warfarin–Sorafenib Interactions in Whites and Asians. Pharmacogenomics 2020, 21 (12) , 853-862. https://doi.org/10.2217/pgs-2020-0036
60. Sherry Torkos, Rhonda Dorren, Michael T. Murray. Vaccinium macrocarpon (Cranberry). 2020, 890-896.e3. https://doi.org/10.1016/B978-0-323-43044-9.00121-7
61. Iain J. W. McKean, Joanna C. Sadler, Anibal Cuetos, Amina Frese, Luke D. Humphreys, Gideon Grogan, Paul A. Hoskisson, Glenn A. Burley. S ‐Adenosyl Methionine Cofactor Modifications Enhance the Biocatalytic Repertoire of Small Molecule C ‐Alkylation. Angewandte Chemie 2019, 131 (49) , 17747-17752. https://doi.org/10.1002/ange.201908681
62. Iain J. W. McKean, Joanna C. Sadler, Anibal Cuetos, Amina Frese, Luke D. Humphreys, Gideon Grogan, Paul A. Hoskisson, Glenn A. Burley. S ‐Adenosyl Methionine Cofactor Modifications Enhance the Biocatalytic Repertoire of Small Molecule C ‐Alkylation. Angewandte Chemie International Edition 2019, 58 (49) , 17583-17588. https://doi.org/10.1002/anie.201908681
63. Patricia Lorena Cîmpan, Romeo Ioan Chira, Mihaela Mocan, Florin Petru Anton, Anca Daniela Farcaş. Oral Anticoagulant Therapy—When Art Meets Science. Journal of Clinical Medicine 2019, 8 (10) , 1747. https://doi.org/10.3390/jcm8101747
64. Osama Y. Alshogran. Warfarin Dosing and Outcomes in Chronic Kidney Disease: A Closer Look at Warfarin Disposition. Current Drug Metabolism 2019, 20 (8) , 633-645. https://doi.org/10.2174/1389200220666190701095807
65. Vera S. Donnenberg, Philip Chaikin, Maja Mandic, Bernd Meibohm, John van den Anker, Erin Rhinehart, Anne N. Nafziger, James F. Burris, . Core Entrustable Professional Activities in Clinical Pharmacology for Entering Residency: Common Problem Drugs and How to Prescribe Them. The Journal of Clinical Pharmacology 2019, 59 (7) , 915-922. https://doi.org/10.1002/jcph.1389
66. Mohammad K. Parvez, Vikas Rishi. Herb-Drug Interactions and Hepatotoxicity. Current Drug Metabolism 2019, 20 (4) , 275-282. https://doi.org/10.2174/1389200220666190325141422
67. Palden Wangyel Dorji, Gyem Tshering, Kesara Na‐Bangchang. CYP2C9, CYP2C19, CYP2D6 and CYP3A5 polymorphisms in South‐East and East Asian populations: A systematic review. Journal of Clinical Pharmacy and Therapeutics 2019, 14 https://doi.org/10.1111/jcpt.12835
68. Shuhei Kobayashi, Koji Ishii, Yasuko Yamada, Emi Ryu, Junya Hashizume, Seiichi Nose, Tetsuya Hara, Mikiro Nakashima, Kaname Ohyama. Combination index of the concentration and in vivo antagonism activity of racemic warfarin and its metabolites to assess individual drug responses. Journal of Thrombosis and Thrombolysis 2019, 47 (3) , 467-472. https://doi.org/10.1007/s11239-018-1780-5
69. Yun Kim, Oliver Hatley, Su‐jin Rhee, Sojeong Yi, Hyun A. Lee, Sumin Yoon, Jae‐Yong Chung, Kyung‐Sang Yu, Howard Lee. Development of a Korean‐specific virtual population for physiologically based pharmacokinetic modelling and simulation. Biopharmaceutics & Drug Disposition 2019, 40 (3-4) , 135-150. https://doi.org/10.1002/bdd.2178
70. Arinao Ndadza, Nicholas Ekow Thomford, Stanley Mukanganyama, Ambroise Wonkam, Mpiko Ntsekhe, Collet Dandara. The Genetics of Warfarin Dose–Response Variability in Africans: An Expert Perspective on Past, Present, and Future. OMICS: A Journal of Integrative Biology 2019, 23 (3) , 152-166. https://doi.org/10.1089/omi.2019.0018
71. Arinao Ndadza, Zinhle Cindi, Edson Makambwa, Emile Chimusa, Ambroise Wonkam, Andre P. Kengne, Mpiko Ntsekhe, Collet Dandara. Warfarin Dose and CYP2C Gene Cluster: An African Ancestral-Specific Variant Is a Strong Predictor of Dose in Black South African Patients. OMICS: A Journal of Integrative Biology 2019, 23 (1) , 36-44. https://doi.org/10.1089/omi.2018.0174
72. Dakota L. Pouncey, Jessica H. Hartman, Page C. Moore, David J. Dillinger, Kimberly W. Dickerson, Daniel R. Sappington, Eugene S. Smith, Gunnar Boysen, Grover P. Miller. Novel isomeric metabolite profiles correlate with warfarin metabolism phenotype during maintenance dosing in a pilot study of 29 patients. Blood Coagulation & Fibrinolysis 2018, 29 (7) , 602-612. https://doi.org/10.1097/MBC.0000000000000752
73. Nhung Phuong Vu, Thuong Thi Huyen Ma, Ngoc Thi Bich Tran, Hue Thi Thu Huynh, Ton Dang Nguyen, Duong Thuy Nguyen, Hai Van Nong, Ming Ta Michael Lee, Ha Hai Nguyen. Polymorphic analysis of CYP2C9 gene in Vietnamese population. Molecular Biology Reports 2018, 45 (5) , 893-900. https://doi.org/10.1007/s11033-018-4235-3
74. Emmanuel Oluwasegun Adawaren, Lilian Mukandiwa, Emmanuel Mfotie Njoya, Lizette Bekker, Neil Duncan, Vinny Naidoo. The use of liver slices from the Cape vulture ( Gyps coprotheres ) to better understand the role of liver toxicity of non-steroidal anti-inflammatory drugs (NSAIDs) in vultures. Environmental Toxicology and Pharmacology 2018, 62 , 147-155. https://doi.org/10.1016/j.etap.2018.07.001
75. Carolina Vázquez, María Orlova, Paula Scibona, Bruno L. Ferreyro, Victoria Otero, Esteban G. Jáuregui, Jorge Arbelbide, Waldo H. Belloso. Clinical and genetic factors influencing acenocoumarol dosing. Blood Coagulation & Fibrinolysis 2018, 29 (6) , 496-500. https://doi.org/10.1097/MBC.0000000000000746
76. Babiker M. El-Haj, Samrein B. M. Ahmed, Mousa A. Garawi, Heyam S. Ali. Linking Aromatic Hydroxy Metabolic Functionalization of Drug Molecules to Structure and Pharmacologic Activity. Molecules 2018, 23 (9) , 2119. https://doi.org/10.3390/molecules23092119
77. Dan M. Roden, Sara L. Van Driest, Jonathan D. Mosley, Quinn S. Wells, Jamie R. Robinson, Joshua C. Denny, Josh F. Peterson. Benefit of Preemptive Pharmacogenetic Information on Clinical Outcome. Clinical Pharmacology & Therapeutics 2018, 103 (5) , 787-794. https://doi.org/10.1002/cpt.1035
78. Abdelhak Elkhazraji, El Arbi Bouaiti, Hassan Boulahyaoui, Christiana philippa Nahmtchougli, Hafid Zahid, Mounia Bensaid, Azeddine Ibrahimi, Nezha Messaoudi. Effect of CYP2C9, VKORC1, CYP4F2, and GGCX gene variants and patient characteristics on acenocoumarol maintenance dose: Proposal for a dosing algorithm for Moroccan patients. Drug Discoveries & Therapeutics 2018, 12 (2) , 68-76. https://doi.org/10.5582/ddt.2017.01063
79. Ann Daly, Allan Rettie, Douglas Fowler, John Miners. Pharmacogenomics of CYP2C9: Functional and Clinical Considerations. Journal of Personalized Medicine 2018, 8 (1) , 1. https://doi.org/10.3390/jpm8010001
80. Lindsay Henderson, Katrina Claw, Erica Woodahl, Renee Robinson, Bert Boyer, Wylie Burke, Kenneth Thummel. P450 Pharmacogenetics in Indigenous North American Populations. Journal of Personalized Medicine 2018, 8 (1) , 9. https://doi.org/10.3390/jpm8010009
81. Katherine E. Horak, Penny M. Fisher, Brian Hopkins. Pharmacokinetics of Anticoagulant Rodenticides in Target and Non-target Organisms. 2018, 87-108. https://doi.org/10.1007/978-3-319-64377-9_4
82. F.P. Guengerich. Cytochrome P450 Enzymes. 2018, 54-86. https://doi.org/10.1016/B978-0-12-801238-3.01960-7
83. Gwendolyn A. McMillin, Mia Wadelius, Victoria M. Pratt. Pharmacogenetics. 2018, 295-327. https://doi.org/10.1016/B978-0-12-816061-9.00011-4
84. Aleksi Tornio, Janne T. Backman. Cytochrome P450 in Pharmacogenetics: An Update. 2018, 3-32. https://doi.org/10.1016/bs.apha.2018.04.007
85. Pascal Vranckx, , Marco Valgimigli, , Hein Heidbuchel, . The Significance of Drug–Drug and Drug–Food Interactions of Oral Anticoagulation. Arrhythmia & Electrophysiology Review 2018, 7 (1) , 55. https://doi.org/10.15420/aer.2017.50.1
86. Sébastien Lefebvre, Isabelle Fourel, Stéphane Queffélec, Dominique Vodovar, Bruno Mégarbane, Etienne Benoit, Virginie Siguret, Virginie Lattard. Poisoning by Anticoagulant Rodenticides in Humans and Animals: Causes and Consequences. 2017https://doi.org/10.5772/intechopen.69955
87. Theodore Wigle, Laura Jansen, Wendy Teft, Richard Kim. Pharmacogenomics Guided-Personalization of Warfarin and Tamoxifen. Journal of Personalized Medicine 2017, 7 (4) , 20. https://doi.org/10.3390/jpm7040020
88. Jia Sun, Yuan Lu, Yueting Li, Jie Pan, Chunhua Liu, Zipeng Gong, Jing Huang, Jiang Zheng, Lin Zheng, Yongjun Li, Ting Liu, Yonglin Wang. Influence of Shenxiong Glucose Injection on the Activities of Six CYP Isozymes and Metabolism of Warfarin in Rats Assessed Using Probe Cocktail and Pharmacokinetic Approaches. Molecules 2017, 22 (11) , 1994. https://doi.org/10.3390/molecules22111994
89. Yasushi Yamazoe, Kouichi Yoshinari. Prediction of regioselectivity and preferred order of metabolisms on CYP1A2-mediated reactions. Part 2: Solving substrate interactions of CYP1A2 with non-PAH substrates on the template system. Drug Metabolism and Pharmacokinetics 2017, 32 (5) , 229-247. https://doi.org/10.1016/j.dmpk.2017.05.004
90. Asuna Senda, Yuji Mukai, Toru Hayakawa, Yuka Kato, Erik Eliasson, Anders Rane, Takaki Toda, Nobuo Inotsume. Angiotensin II Receptor Blockers Inhibit the Generation of Epoxyeicosatrienoic Acid from Arachidonic Acid in Recombinant CYP 2C9, CYP 2J2 and Human Liver Microsomes. Basic & Clinical Pharmacology & Toxicology 2017, 121 (4) , 239-245. https://doi.org/10.1111/bcpt.12789
91. Aisha Qayyum, Muzammil Hasan Najmi, Qaisar Mansoor, Zia-ur-Rehman Farooqi, Abdul Khaliq Naveed, Andleeb Hanif, Syed Ali Raza Kazmi, Muhammad Ismail. Frequency of Common CYP2C9 Polymorphisms and Their Impact on Warfarin Dose Requirement in Pakistani Population. Clinical and Applied Thrombosis/Hemostasis 2017, 23 (7) , 800-806. https://doi.org/10.1177/1076029616654264
92. Liang Gong, Cong-Min Zhang, Jin-Feng Lv, Hong-Hao Zhou, Lan Fan. Polymorphisms in cytochrome P450 oxidoreductase and its effect on drug metabolism and efficacy. Pharmacogenetics and Genomics 2017, 27 (9) , 337-346. https://doi.org/10.1097/FPC.0000000000000297
93. Nianjun Liu, Marguerite R Irvin, Degui Zhi, Amit Patki, T Mark Beasley, Deborah A Nickerson, Charles E Hill, Jinbo Chen, Stephen E Kimmel, Nita A Limdi. Influence of Common and Rare Genetic Variation on Warfarin Dose Among African–Americans and European–Americans Using the Exome Array. Pharmacogenomics 2017, 18 (11) , 1059-1073. https://doi.org/10.2217/pgs-2017-0046
94. . Physicochemical and Biopharmaceutical Factors Affecting Hepatic/Intestinal First‐Pass Effect. 2017, 173-201. https://doi.org/10.1002/9781118916926.ch5
95. Monique Groen-Wijnberg, Jan van Dijk, Walter Krauwinkel, Virginie Kerbusch, John Meijer, Reiner Tretter, Wenhui Zhang, Marcel van Gelderen. Pharmacokinetic Interactions Between Mirabegron and Metformin, Warfarin, Digoxin or Combined Oral Contraceptives. European Journal of Drug Metabolism and Pharmacokinetics 2017, 42 (3) , 417-429. https://doi.org/10.1007/s13318-016-0350-5
96. Elliot Offman, Michael Davidson, Catarina Nilsson. No Effect of Omega-3 Carboxylic Acids on Pharmacokinetics/Pharmacodynamics of Warfarin or on Platelet Function When Co-administered with Acetylsalicylic Acid: Results of Two Phase I Studies in Healthy Volunteers. American Journal of Cardiovascular Drugs 2017, 17 (3) , 251-260. https://doi.org/10.1007/s40256-017-0217-4
97. Darcy R. Flora, Allan E. Rettie, Richard C. Brundage, Timothy S. Tracy. CYP2C9 Genotype‐Dependent Warfarin Pharmacokinetics: Impact of CYP2C9 Genotype on R‐ and S‐Warfarin and Their Oxidative Metabolites. The Journal of Clinical Pharmacology 2017, 57 (3) , 382-393. https://doi.org/10.1002/jcph.813
98. Chanan Shaul, Simcha Blotnick, Mordechai Muszkat, Meir Bialer, Yoseph Caraco. Quantitative Assessment of CYP2C9 Genetic Polymorphisms Effect on the Oral Clearance of S-Warfarin in Healthy Subjects. Molecular Diagnosis & Therapy 2017, 21 (1) , 75-83. https://doi.org/10.1007/s40291-016-0247-7
99. Bernadette Espana, Solange Couturier, Caroline Prouillac. Role of ABC transporters in trans‐epithelial transport of vitamin K antagonists. Biopharmaceutics & Drug Disposition 2017, 38 (1) , 20-32. https://doi.org/10.1002/bdd.2055
100. Lauren E. Walker, Anna Stewart, Sir Munir Pirmohamed. Stroke Pharmacogenetics. 2017, 327-410. https://doi.org/10.1007/978-3-319-56210-0_17